Design, synthesis, molecular docking study and molecular dynamics simulation of new coumarin-pyrimidine hybrid compounds having anticancer and antidiabetic activity

Coumarin-pyrimidine hybrid compounds were synthesized by condensation reaction of alpha,beta-unsaturated ketones of 6-acetyl-5hydroxy-4-methylcoumarin with guanidine. The reaction yields were of 42-62%. The antidiabetic and anticancer activities of these compounds were examined. These compounds displayed low toxicity to two cancer cell lines (including KB and HepG2 ones), but exhibited remarkably active against alpha-amylase with IC50 values of 102.32 +/- 1.15 mu M to 249.52 +/- 1.14 mu M and against alpha-glucosidase with IC50 values of 52.16 +/- 1.12 mu M to 184.52 +/- 1.15 mu M. Amongst these compounds, 6c was the best inhibitory activity against alpha-amylase, and 6f had the highest activity against alpha-glucosidase. The kinetics of inhibitor 6f was competitive alpha-glucosidase inhibitor property. ADMET predictions showed that almost all synthesized compounds exhibited drug-like activity. IFD and MD simulations were carried out on enzymes 4W93 and 5NN8 to elucidate inhibitory potential of 6c and 6f against tested enzymes. The binding free energy calculation by MM-GBSA approach showed that Coulomb, lipophilic and van der Waals energy terms are major contributors for the inhibitor binding. Molecular dynamics simulations in water solvent system were carried out for the 6f/5NN8 complex to elucidate the variability of active interactions between ligand 6f and active pockets of this enzyme.